TiCARos’ Converter platform uses a chimeric CTLA4 mutant composed of an extracellular CTLA4 domain and an intracellular cluster of differentiation 28 (CD28) domain (a CTLA4–CD28 chimera).
To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback